Monroe1
1 hour ago
They should be shaking scared about now. "As for the industry’s initial reactions on the innovation front, the Pharmaceutical Research and Manufacturers of America (PhRMA) wants to “work with his administration to further strengthen our innovation ecosystem that enables the United States to lead the world in medicine development,” CEO Stephen Ubl said in a statement. “New medicines are transforming our ability to prevent, treat, and cure deadly disease, improving patient lives and helping to avoid the most expensive parts of our health care system.”
"“We are committed to working with the Trump administration and the new Congress to make our health care system work better for patients while preserving our unique ecosystem that enables greater innovation and lower costs for patients,” Ubl said.
Of course, a recent twist in Trump’s later campaign days was the introduction of Robert F. Kennedy Jr. as a prospect to head up healthcare. Kennedy, who scrapped his own campaign for the presidency in August, is widely known for his anti-vaccine rhetoric and conspiracies and was even temporarily banned from Instagram in 2021 for spreading misinformation about COVID-19 vaccines. At a rally in New York, Trump pledged to, if elected, allow Kennedy to “go wild on health” as well as “the medicines.”
Kennedy later delivered a grim message to the FDA on X, formerly Twitter, warning those who “work for the FDA and are part of this corrupt system” to “1. Preserve your records, and 2. Pack your bags.” Today, Fierce Biopharma
Monroe1
2 days ago
Analysts Adjust Pfizer Projections, Citing Uncertain Q4 Outlook
Nauman Khan
Mon, November 4, 2024 at 10:11 a.m. CST 1 min read
In This Article:
PFE
-0.96%
Leerink Partners has lowered its fourth-quarter 2024 EPS estimate for New York-based pharmaceutical giant Pfizer (PFE, Financial), adopting a conservative stance for the quarter. The firm reduced its EPS forecast from $0.79 to $0.63. Despite this adjustment, Pfizer recently outperformed expectations in Q3, reporting an EPS of $1.06 compared to the market consensus of just $0.64. This surge in performance was bolstered by an exceptional increase in revenue, which reached $17.70 billion, significantly surpassing market expectations of $14.92 billion.
Warning! GuruFocus has detected 8 Warning Signs with PFE.
This performance has led to year-over-year revenue growth of 31.2%, indicating that Pfizer has a strong market base despite its worst financial outlook. However, Leerink downgraded P and forecasted concerns about the firm's future earning capabilities, which puts a more cautious view than the current market. The outlook is a moderate buy with a target price of $33.58.
The broader analyst community has given some ratings upgrades, and despite a recent cut, they highlight a cautiously optimistic scenario. Exclusive: Citigroup and Sanford C. Bernstein have retained neutral calls as the industry dynamics play out. UBS and Wells Fargo have marginally lifted their target prices following their steady market journey.
Businesspeople appear uncertain, and something has changed as Pfizer's shares dropped to $28.08; however, institutional buying persists. The hedge funds and financial industry players, such as LGT Group Foundation and Creative Planning, have continued to flock significant funds toward Pfizer for further investment due to the organization's affluent prospects in the biopharmaceutical industry.
Pfizer is well aware of the current market and regulatory systems worldwide, and yet the world looks at this company's financial status against the backdrop of constant emerging health crises and competitors.
This article first appeared on GuruFocus.
DewDiligence
1 week ago
PFE reports 3Q24 results—raises_2024_guidance_for Paxlovid, non-GAAP EPS:
https://s28.q4cdn.com/781576035/files/doc_financials/2024/q3/Q3-2024-PFE-Earnings-Release-Final.pdf
3Q24 highlights
• 3Q24 revenue was $17.7B, +32% YoY.
• 3Q24 oncology sales were $4.0B, +30% YoY, including an $854M contribution from former SGEN products.
• 3Q24 Comirnaty and Paxlovid sales were $1.4B and $2.7B, respectively; both products benefitted from a mid-summer spike in COVID infections.
• 3Q24 GAAP and non-GAAP EPS were $0.78 and $1.06, respectively. (3Q23 GAAP and non-GAAP EPS were losses.)
2024 full-year guidance
• 2024 revenue guidance is now $61-64B, up from the prior guidance of $59.5-62.5B, given three months ago. The $1.5B increase in revenue guidance is due to a $2B increase for Paxlovid (from to $3.5B to $5.5B), and a $500M decrease for all other products, largely due to the withdrawal from the market of Oxbryta.
• 2024 non-GAAP EPS guidance is now $2.75-2.95, up $0.30 at both ends from the guidance given three months. (Both the old and the new guidance ranges include a negative $0.40 hit from SGEN, most of which stems from the net interest expense on the $43B of net debt PFE took on to fund the acquisition.)
• 2024 Comirnaty sales guidance is $5B, unchanged from the guidance three months ago.
3Q24 CC slides:
https://investors.pfizer.com/files/doc_financials/2024/q3/Q3-2024-Earnings-Charts_FINAL.pdf
3Q24 CC prepared remarks (synched with slides):
https://s28.q4cdn.com/781576035/files/doc_financials/2024/q3/Q3-2024-Earnings-Conference-Call-Prepared-Remarks-FINAL.pdf
Monroe1
1 week ago
Bill Gates ain't laughin... Bill Gates Humbled Like Pie As.....Bill Gates Humbled Like Pie As 'Vax' Trial Draws Near Fast: November 27, 2024 | Yes, ‘Even if … your name is Bill Gates, you still have to go to court’
Not only is there a Nuremberg Hearing in Costa Rica starting November 11 about Gates and his vax peddler cohorts, but huge BOOM, Netherlands Judge Rules Covid Vaccine Lawsuit Can Proceed November 27!
Interest of Justice
Oct 28, 2024
https://interestofjustice.substack.com/p/bill-gates-humbled-like-pie-as-vax?publication_id=825071&post_id=150615739&isFreemail=true&r=47wykb&triedRedirect=true
Anyone who was injured or had family and friends who died or are currently suffering from the numerous secondary affects of the jab, should read this so send it out.
north40000
1 week ago
Would that sale of stock be used by PFE for other cash M/A purposes? There is a report today on the AMRN board that Alex Denner, head of Sarissa Capital HF, has bought shares of PFE, urging among other things that PFE engage in more M/A activity. Starboard has also bought substantial shares of PFE. There seems to be some confusion on AMRN board whether Sarissa has bought any shares of PFE.
We know of past PFE interest in AMRN's Vascepa drug that reduces risk from CVDs, having approached HLS Therapeutics, an AMRN Canadian partner, to sell Vascepa to GPs in Canada about 2 or 3 years ago. HLS recently terminated that extant agreement with PFE. We also know Sarissa Capital owns a little less than 10% of AMRN shares, believing AMRN stock to be "undervalued." Finally, we also now know that AMRN and its partners ROW have achieved state government approvals of Vascepa, and that negotiations of remuneration with state governments for patient remuneration of cost of Vascepa are underway or concluded--Vascepa is being sold in Canada, Spain and the U.K.
DewDiligence
2 weeks ago
PFE—FDA expands Abrysvo label_to_high-risk_adults_age 18+, providing a (presumably temporary) competitive advantage in the US RSV-vaccine market:
https://finance.yahoo.com/news/u-fda-approves-pfizer-rsv-204500841.html Among U.S. adults 18 to 49 years of age, 9.5% have an underlying chronic condition, such as obesity, diabetes, chronic obstructive pulmonary disease (COPD), heart failure, chronic kidney disease, and asthma that puts them at increased risk of developing, and being hospitalized for, RSV-associated LRTD, and this rises to 24.3% among those 50 to 64 years of age. Until now, Abrysvo was FDA-approved for: adults age 60+, with or without co-morbidities(#msg-172028729); and for pregnant women, to protect newborns (#msg-172651068). The label expansion to high-risk adults age 18-59 is based on the data in #msg-174204266.
The main competition for Abrysvo is GSK’s Arexvy, which is FDA-approved for high-risk adults age 50+ (#msg-174567339).
After a strong initial burst, sales of Abrysvo and GSK’s Arexvy have been soft (#msg-175205710). Sales have been hampered by the tepid endorsement from the CDC, whose recommendation for RSV vaccines has a lower age bound of 75 for individuals without co-morbidities (#msg-174664202).